Novo Nordisk reported results on November 16, 2026 from STEP Young, a phase 3 trial of once-weekly injectable semaglutide in children aged 6 to under 12 with obesity. The study, funded by Novo Nordisk, was published in The New England Journal of Medicine.
What the trial found
Researchers randomised 167 children to semaglutide or placebo. Both groups received lifestyle counselling. At 68 weeks, the primary analysis found that mean body mass index (BMI) fell 13.5% in the semaglutide group and rose 2.7% in the placebo group, an estimated difference of 16.2 percentage points.
In a separate analysis that assumed participants followed their assigned treatment and did not use other weight-management interventions, Novo Nordisk reported that nearly 80% of participants receiving semaglutide reached a BMI reduction of at least 10%, compared with none receiving placebo.
Safety and regulatory context
The researchers reported adverse events in 96% of participants receiving semaglutide and 93% receiving placebo. Gastrointestinal events were more frequent with semaglutide and led one participant in that group to discontinue treatment. The use studied in children aged 6 to under 12 was investigational.
Sources: STEP Young study in The New England Journal of Medicine and Novo Nordisk’s announcement. Logo supplied by Novo Nordisk’s press representative.







